Answers are grounded in this paper and cite their sources.
Assesses cybersecurity certification of diabetes devices, highlighting low compliance rates.
Introduction and Objective: Secure data transmission in diabetes devices is critical to protect patient information and ensure safe operation of connected diabetes management systems. The FDA mandates that connected diabetes devices must meet or exceed their cybersecurity guidelines. The Institute of Electrical and Electronics Engineers (IEEE) Standard 2621 establishes baseline cybersecurity requirements for these devices. Diabetes Technology Society Cybersecurity Standard for Connected Diabetes Devices (DTSec) is a complementary standard and certification program that folded into IEEE 2621. We assessed whether the connected devices listed in the 2025 ADA Consumer Guide as well as spinal cord stimulators (SCSs, used for diabetic neuropathy pain), are formally certified by IEEE 2621 or DTSec. Methods: Devices were eligible if they appeared in the 2025 ADA Consumer Guide and used wireless connectivity. Devices, including BGMs, CGMs, and insulin pumps, were cross-referenced with official IEEE 2621 and DTSec certification lists to determine standard adherence. SCSs were also evaluated. The primary outcome was the proportion of devices certified by each standard. Results: Among 29 BGMs, one held DTSec certification (3.4%) and one held both IEEE 2621 and DTSec certification (3.4%). Of eight CGMs, one was certified under IEEE 2621 (12.5%). Among six insulin pumps, one had DTSec certification (16.7%). No smart insulin pens, single injection aids, or SCSs met either standard (0%). Overall, among 52 eligible devices, one was certified under IEEE 2621 (1.9%), two under DTSec (3.8%), and one met both (1.9%). Conclusion: Certification to IEEE 2621 and DTSec cybersecurity standards for diabetes devices is rare. Greater manufacturer engagement and demand by patients, clinicians, and payers is needed to increase adherence. Meeting IEEE 2621 will result in greater confidence by stakeholders in the security of these devices and support a safe digital health ecosystem. Future efforts should focus on improving awareness to create demand by stakeholders affected by the safety of diabetes devices. Disclosure A.F. Scheideman: None. M. Shao: None. A.A. Abdel-Malek: Stock/Shareholder; Current; Thirdwayv Inc., Apex Medical Ai Inc. R. Subramaniam: None. N. Schwartz: None. D. Klonoff: Advisory Panel; Current; Afon Technology, Atropos Health, Embecta, Glooko, Inc., Glucotrack, Lifecare, Inc. Advisory Panel; Ended; Novo Nordisk. Advisory Panel; Current; Sanofi, Synchneuro, Thirdwayv Inc.
No takes yet. Share an insight, caveat, or question.
Scheideman et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: